Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. (OTCBB:OPLI) released results from a 24 week, placebo-controlled…
CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome
No comments:
Post a Comment